<DOC>
	<DOC>NCT02390037</DOC>
	<brief_summary>The objective of the study is to assess the incidence of safety outcomes in patients treated with Pipeline™ Flex embolization device with Shield Technology™.</brief_summary>
	<brief_title>Pipeline™ Flex Embolization Device With Shield Technology™ Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<criteria>1. Subject has provided written informed consent using the IRB/ECapproved consent form and agrees to comply with protocol requirements. 2. Age 1880 years. 3. Subject has already been selected for flow diversion therapy as the appropriate treatment. 4. Subject has an unruptured target intracranial aneurysm (IA). 5. Subject has a target IA located in the anterior or posterior circulation. 1. Major surgery in the past 30 days. 2. Any known contraindication to treatment with the Pipeline™ Flex embolization device with Shield Technology™ per Instructions for Use. 3. Pregnant or breastfeeding women or women who wish to become pregnant during the length of study participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>